{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:09:35Z","timestamp":1790273375233,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01021-y","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:37:09Z","timestamp":1790271429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Zilucoplan Versus Intravenous Immunoglobulin, Eculizumab, and Ravulizumab Using Matching-Adjusted Indirect Comparisons"],"prefix":"10.1007","author":[{"given":"April","family":"Betts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiju","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhiroop","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitender","family":"Takyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arju","family":"Dhawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Barnett","family":"Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4632-6097","authenticated-orcid":false,"given":"Vikalp","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"issue":"21","key":"1021_CR1","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.3390\/jcm11216394","volume":"11","author":"D S\u00e1nchez-Tejerina","year":"2022","unstructured":"S\u00e1nchez-Tejerina D, Sotoca J, Llaurado A, et al. New targeted agents in myasthenia gravis and future therapeutic strategies. J Clin Med. 2022;11(21):6394.","journal-title":"J Clin Med"},{"key":"1021_CR2","unstructured":"US National Institutes of Health (NIH). Myasthenia gravis. 2024. https:\/\/www.ninds.nih.gov\/health-information\/disorders\/myasthenia-gravis. Accessed November 2025."},{"key":"1021_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"1021_CR4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A. New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs. 2025;39(2):185\u2013213.","journal-title":"BioDrugs"},{"key":"1021_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1277596","volume":"14","author":"PP San","year":"2023","unstructured":"San PP, Jacob S. Role of complement in myasthenia gravis. Front Neurol. 2023;14:1277596.","journal-title":"Front Neurol"},{"key":"1021_CR6","unstructured":"UCB. UCB announces U.S. FDA approval of ZILBRYSQ[\u00ae] (zilucoplan) for the treatment of adults with generalized myasthenia gravis. 2023. https:\/\/www.ucb.com\/stories-media\/Press-Releases\/article\/UCB-announces-US-FDA-approval-of-ZILBRYSQR-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis. Accessed November 2025"},{"key":"1021_CR7","unstructured":"European Medicines Agency (EMA). Zilbrysq: Zilucoplan. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zilbrysq. Accessed November 2025."},{"issue":"2","key":"1021_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2018.01.006","volume":"36","author":"C Barnett","year":"2018","unstructured":"Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. Measuring clinical treatment response in myasthenia gravis. Neurol Clin. 2018;36(2):339\u201353.","journal-title":"Neurol Clin"},{"issue":"5","key":"1021_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mus.23988","volume":"49","author":"HD Katzberg","year":"2014","unstructured":"Katzberg HD, Barnett C, Merkies IS, Bril V. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial. Muscle Nerve. 2014;49(5):661\u20135.","journal-title":"Muscle Nerve"},{"issue":"4","key":"1021_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-026-04214-y","volume":"35","author":"\u00c2J Ben","year":"2026","unstructured":"Ben \u00c2J, Brackx F, Phillips G. Estimating the minimal clinically important difference for the Myasthenia Gravis Quality of Life revised scale (MG-QOL15R). Qual Life Res. 2026;35(4):101.","journal-title":"Qual Life Res"},{"issue":"7","key":"1021_CR11","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000201501","volume":"100","author":"V Bril","year":"2023","unstructured":"Bril V, Szczudlik A, Vaitkus A, et al. Randomized double-blind placebo-controlled trial of the corticosteroid-sparing effects of immunoglobulin in myasthenia gravis. Neurology. 2023;100(7):e671\u201382.","journal-title":"Neurology"},{"issue":"23","key":"1021_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017\u201323.","journal-title":"Neurology"},{"key":"1021_CR13","unstructured":"ClinicalTrials.gov. Safety, tolerability, and efficacy of zilucoplan in subjects with generalized myasthenia gravis (RAISE). 2024; https:\/\/clinicaltrials.gov\/study\/NCT04115293. Accessed November 2025."},{"key":"1021_CR14","unstructured":"ClinicalTrials.gov. Safety and efficacy of eculizumab in refractory generalized myasthenia gravis (REGAIN Study). 2019. https:\/\/clinicaltrials.gov\/study\/NCT01997229. Accessed November 2025."},{"key":"1021_CR15","unstructured":"ClinicalTrials.gov. CHAMPION: Safety and efficacy study of ravulizumab in adults with generalized myasthenia gravis. 2024. https:\/\/clinicaltrials.gov\/study\/NCT03920293. Accessed November 2025."},{"issue":"5","key":"1021_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mus.22140","volume":"44","author":"S Muppidi","year":"2011","unstructured":"Muppidi S, Wolfe GI, Conaway M, Burns TM. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727\u201331.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1021_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40263-024-01062-7","volume":"38","author":"Y Ma","year":"2024","unstructured":"Ma Y, Nie X, Zhu G. The efficacy and safety of different targeted drugs for the treatment of generalized myasthenia gravis: a systematic review and Bayesian network meta-analysis. CNS Drugs. 2024;38(2):93\u2013104.","journal-title":"CNS Drugs"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01021-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01021-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01021-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:37:18Z","timestamp":1790271438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01021-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":17,"alternative-id":["1021"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01021-y","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Carolina Barnett Tapia has served as member of the advisory board for argenx, Alexion, UCB, Janssen and NMD Pharma; has been a consultant for argenx, Janssen, Novartis, and UCB; and has received research support from US Department of Defense, Muscular Dystrophy Canada, and MGNet. She is the primary developer of the MGII and may receive royalties. Saiju Jacob has served as an international advisory board member for Alexion, Alnylam, argenx, Immunovant, Johnson and Johnson, Merck, Novartis, Regeneron and UCB; is currently an expert panel member of the Myasthenia Gravis consortium for argenx and UCB; and has received speaker fees from Terumo BCT and Eisai Pharmaceuticals. April Betts is employed by UCB. Vikalp Maheshwari, Abhiroop Chakravarty, Jitender Takyar, and Arju Dhawan are employed by Parexel International, which was hired by UCB Pharma to collaborate on this study.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}